Data obtained further indicate that such lumican-related structural changes are likely to sharply modulate tumor stromal reaction as well as response to matrix-targeting therapeutic strategies, as demonstrated considering TAX2 peptide treatment. This evidence concerns the gene LUM and neoplasm.